MedMira has announced today that it has filed a provisional patent application for a system which enables over-the-counter (OTC) home testing and diagnosis of infectious diseases, such as HIV, hepatit
Pharmaceutical company, Novogen, has been granted patent coverage over its OTC products being sold in Canada. The patent covers the isoflavone composition of the products Promensil(TM), Rimostil(TM) an
Vasamed, developer and supplier of hemodynamic monitoring products, announced that the U.S. Patent and Trademark Office granted it a method patent for a novel pulse oximeter that incorporates signals
QRS Diagnostic, a designer and developer of software-based medical devices, has announced that the United States Patent and Trademark Office approved a new patent on its design of medic
After Ellen Van't Hof survived a bilateral mastectomy, six months of chemotherapy and two months of radiation she thought the worst was behind her. And then she noticed her right arm was becoming swollen. The verdict: lymphedema, an accumulation of lymp
Morphotek, Inc. announced today the issuance of United States Patent 6,737,268 covering the generation of genetically enhanced therapeutic antigens. The issued patent covers the use of the company's
A patent for a highly sensitive test to detect the presence of the "date rape" drug, GHB, has recently been granted to the University of California, Santa Barbara. Several companies have expressed interest in developin
Xenobiotic Detection Systems, Inc. has announced that their most recent patent application (number US 6,720,431 B2) has been approved. XDS consultant (and former XDS laboratory director) Michael
MorphoSys AG announced today that the U.S. Patent & Trademark Office has granted a new patent on its proprietary CysDisplay? screening technology. CysDisplay? is an important component o
Cancer cells have the ability to invade blood vessels and find their way into the bloodstream. Once there, these infected cells can easily travel to other parts of the body and attack healthy organs. While migration and deformability have been
Date: Tuesday, 16-Jan-2007
CogState has announced that it has been issued a patent from the Unites States Patent & Trade Mark Office (US patent no. 7,163,513) for the key technology platform used in its computer-based tests of brain function. The patent term adjustment is 229 days.As announced in July 2006, this patent broadly protects CogState's psychological testing method which randomises the nature and timing of the visual stimuli presented to a subject as well as the apparatus used in such tests. The patent also protects the company's unique approach to cross cultural and non language specific based testing which uses a cultural visual stimuli.
This is the first US patent for CogState, which also holds a patent in Australia (patent number 2001275604), issued in April 2005.
CogState Ltd (ASX: CGS) specialises in the development and commercialisation of rapid, computerised diagnostic tests of cognition (brain function). The tests are sold to pharmaceutical, biotechnology, nutraceutical and functional food companies to quantify the effect of drugs or other interventions on human subjects participating in clinical trials.
Since sales into the clinical trials market began in 2004, CogState has secured agreements with organisations including Pfizer, Merck, GlaxoSmithKline, Centres for Disease Control (USA), ALZA Corporation (a member of the Johnson and Johnson group) and Organon USA. CogState is currently expanding its existing activities in the US clinical trial markets.
http://www.cogstate.com